LUCIA, the second of 2 pivotal phase 3 trials in neovascular (wet) age-related macular degeneration (AMD), missed its primary ...
The 2 complement inhibitors approved by the US Food and Drug Administration (FDA) for geographic atrophy (GA) secondary to ...
SpyGlass Pharma has reported 4-year interim results from the first-in-human (FIH) trial of its Bimatoprost Drug Pad-IOL System (BIM-IOL System), extending what the company describes as the “longest ...
At AAO 2026, Anjum F. Koreishi, MD, shared how to prevent complications after cataract surgery in patients with uveitis.
David F. Chang, MD, shares how to set realistic refractive IOL expectations and streamline patient counseling.
Taken together, these three responses point to gaps beyond the next therapy: in how academic medicine is valued, in what ...
Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.
At AAO 2026, Adam, MD, shares Yamane technique pearls, from docking the trailing haptic to preventing tilt and haptic ...
The FDA has approved Enspryng (satralizumab, Genentech) for thyroid eye disease (TED), making the drug the first subcutaneous ...
Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...
In addition to the results, Roche also announced that the US Food and Drug Administration (FDA) has accepted the company’s ...
David F. Chang, MD, explained how offering complementary refractive IOLs reduces patient anxiety and indecision.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results